Market Closed -
Swiss Exchange
11:30:41 2024-05-31 am EDT
|
5-day change
|
1st Jan Change
|
486.4
CHF
|
-0.45%
|
|
-5.59%
|
+37.52%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
26,224
|
42,255
|
56,574
|
33,615
|
26,273
|
35,078
|
-
|
-
|
Enterprise Value (EV)
1 |
29,185
|
45,068
|
55,616
|
33,429
|
27,195
|
37,904
|
38,603
|
38,620
|
P/E ratio
|
40.8
x
|
48.9
x
|
19.3
x
|
27.7
x
|
39.8
x
|
39.7
x
|
31.7
x
|
26.2
x
|
Yield
|
0.78%
|
0.53%
|
0.39%
|
0.66%
|
1.13%
|
0.93%
|
1.08%
|
1.24%
|
Capitalization / Revenue
|
4.43
x
|
6.83
x
|
10.5
x
|
5.4
x
|
3.91
x
|
5.26
x
|
4.55
x
|
4.08
x
|
EV / Revenue
|
4.93
x
|
7.29
x
|
10.3
x
|
5.37
x
|
4.05
x
|
5.68
x
|
5.01
x
|
4.49
x
|
EV / EBITDA
|
18
x
|
26.1
x
|
33.4
x
|
16.8
x
|
13.6
x
|
20.4
x
|
17.6
x
|
15.2
x
|
EV / FCF
|
146
x
|
287
x
|
-449
x
|
-39.2
x
|
-91.6
x
|
-232
x
|
1,015
x
|
132
x
|
FCF Yield
|
0.69%
|
0.35%
|
-0.22%
|
-2.55%
|
-1.09%
|
-0.43%
|
0.1%
|
0.76%
|
Price to Book
|
4.03
x
|
6.2
x
|
5.82
x
|
3.18
x
|
2.76
x
|
3.64
x
|
3.43
x
|
3.16
x
|
Nbr of stocks (in thousands)
|
74,246
|
74,289
|
74,283
|
74,189
|
74,282
|
72,117
|
-
|
-
|
Reference price
2 |
353.2
|
568.8
|
761.6
|
453.1
|
353.7
|
486.4
|
486.4
|
486.4
|
Announcement Date
|
1/21/20
|
1/27/21
|
1/26/22
|
1/25/23
|
1/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5,920
|
6,185
|
5,409
|
6,223
|
6,717
|
6,675
|
7,703
|
8,606
|
EBITDA
1 |
1,624
|
1,728
|
1,665
|
1,995
|
1,999
|
1,860
|
2,188
|
2,542
|
EBIT
1 |
1,249
|
1,358
|
1,151
|
1,397
|
939
|
1,158
|
1,480
|
1,807
|
Operating Margin
|
21.1%
|
21.96%
|
21.28%
|
22.45%
|
13.98%
|
17.35%
|
19.22%
|
20.99%
|
Earnings before Tax (EBT)
1 |
849
|
986
|
760
|
1,448
|
790
|
1,091
|
1,371
|
1,691
|
Net income
1 |
645
|
869
|
2,944
|
1,215
|
654
|
892.9
|
1,109
|
1,349
|
Net margin
|
10.9%
|
14.05%
|
54.43%
|
19.52%
|
9.74%
|
13.38%
|
14.4%
|
15.68%
|
EPS
2 |
8.650
|
11.63
|
39.52
|
16.34
|
8.880
|
12.24
|
15.36
|
18.59
|
Free Cash Flow
1 |
200
|
157
|
-124
|
-852
|
-297
|
-163.3
|
38.04
|
292.5
|
FCF margin
|
3.38%
|
2.54%
|
-2.29%
|
-13.69%
|
-4.42%
|
-2.45%
|
0.49%
|
3.4%
|
FCF Conversion (EBITDA)
|
12.32%
|
9.09%
|
-
|
-
|
-
|
-
|
1.74%
|
11.51%
|
FCF Conversion (Net income)
|
31.01%
|
18.07%
|
-
|
-
|
-
|
-
|
3.43%
|
21.68%
|
Dividend per Share
2 |
2.750
|
3.000
|
3.000
|
3.000
|
4.000
|
4.519
|
5.275
|
6.040
|
Announcement Date
|
1/21/20
|
1/27/21
|
1/26/22
|
1/25/23
|
1/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
2,944
|
3,074
|
3,111
|
2,542
|
2,867
|
2,982
|
3,241
|
3,078
|
3,639
|
3,031
|
3,643
|
EBITDA
1 |
796
|
893
|
835
|
847
|
818
|
987
|
1,008
|
922
|
1,077
|
801.5
|
1,038
|
EBIT
1 |
606
|
706
|
652
|
606
|
545
|
698
|
699
|
563
|
376
|
503.4
|
700.4
|
Operating Margin
|
20.58%
|
22.97%
|
20.96%
|
23.84%
|
19.01%
|
23.41%
|
21.57%
|
18.29%
|
10.33%
|
16.61%
|
19.23%
|
Earnings before Tax (EBT)
1 |
407
|
564
|
422
|
296
|
464
|
594
|
854
|
486
|
304
|
442.9
|
646.4
|
Net income
1 |
346
|
477
|
392
|
319
|
2,625
|
492
|
723
|
410
|
244
|
365.6
|
532.2
|
Net margin
|
11.75%
|
15.52%
|
12.6%
|
12.55%
|
91.56%
|
16.5%
|
22.31%
|
13.32%
|
6.71%
|
12.06%
|
14.61%
|
EPS
2 |
4.640
|
6.390
|
5.240
|
4.280
|
35.24
|
6.610
|
9.730
|
5.540
|
3.340
|
4.990
|
7.270
|
Dividend per Share
2 |
-
|
-
|
3.000
|
3.000
|
-
|
-
|
3.000
|
3.500
|
-
|
4.000
|
-
|
Announcement Date
|
1/21/20
|
7/24/20
|
1/27/21
|
7/23/21
|
1/26/22
|
7/22/22
|
1/25/23
|
7/21/23
|
1/26/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
2,961
|
2,813
|
-
|
-
|
922
|
2,826
|
3,525
|
3,542
|
Net Cash position
1 |
-
|
-
|
958
|
186
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.823
x
|
1.628
x
|
-
|
-
|
0.4612
x
|
1.519
x
|
1.611
x
|
1.394
x
|
Free Cash Flow
1 |
200
|
157
|
-124
|
-852
|
-297
|
-163
|
38
|
293
|
ROE (net income / shareholders' equity)
|
10.1%
|
13.1%
|
35.5%
|
11.9%
|
6.52%
|
9.18%
|
11%
|
12.6%
|
ROA (Net income/ Total Assets)
|
4.65%
|
6.15%
|
19.1%
|
7.19%
|
3.82%
|
5.22%
|
6.25%
|
7.34%
|
Assets
1 |
13,884
|
14,135
|
15,444
|
16,907
|
17,103
|
17,106
|
17,749
|
18,394
|
Book Value Per Share
2 |
87.60
|
91.70
|
131.0
|
143.0
|
128.0
|
134.0
|
142.0
|
154.0
|
Cash Flow per Share
2 |
13.20
|
15.10
|
16.30
|
13.70
|
18.80
|
22.20
|
24.30
|
29.50
|
Capex
1 |
786
|
973
|
1,300
|
1,872
|
1,682
|
1,615
|
1,608
|
1,608
|
Capex / Sales
|
13.28%
|
15.73%
|
24.03%
|
30.08%
|
25.04%
|
24.2%
|
20.87%
|
18.68%
|
Announcement Date
|
1/21/20
|
1/27/21
|
1/26/22
|
1/25/23
|
1/26/24
|
-
|
-
|
-
|
Last Close Price
486.4
CHF Average target price
576.9
CHF Spread / Average Target +18.60% Consensus |
1st Jan change
|
Capi.
|
---|
| +37.52% | 38.82B | | +43.36% | 54.64B | | -5.31% | 39.92B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +25.12% | 12.21B | | +0.04% | 12.16B | | +26.04% | 11.94B | | -11.83% | 10.74B |
Other Biotechnology & Medical Research
|